Background
Idenix Pharmaceuticals held U.S. Patent No. 7,608,597, directed to a method of treating hepatitis C virus (HCV) by administering nucleoside compounds with a specific chemical and stereochemical structure at the 2’ carbon position. Gilead Sciences independently developed sofosbuvir — a blockbuster HCV drug that became the foundation of the highly effective Harvoni and Epclusa treatments, generating billions in annual sales.
Idenix sued Gilead in Delaware, alleging sofosbuvir fell within the scope of Idenix’s broadly written patent. Gilead stipulated to infringement but challenged validity. A jury found the patent valid and awarded Idenix $2.54 billion in damages — one of the largest patent verdicts ever. The district court then entered judgment as a matter of law overturning the verdict on the grounds of invalidity for lack of enablement.
The Court’s Holding
The Federal Circuit affirmed invalidity. The court applied the Wands factors for enablement, which require a patent’s specification to enable a person of ordinary skill in the art to make and use the full scope of the claimed invention without undue experimentation. The court found that Idenix’s claims covered an enormous genus of chemical compounds — potentially billions of distinct molecules — but the specification provided working examples for only a handful of specific compounds. The skilled chemist would face undue experimentation to synthesize and test the vast majority of compounds within the claimed genus to determine which were effective against HCV.
The Federal Circuit also affirmed invalidity for lack of written description, finding the specification did not demonstrate possession of the full scope of the claimed genus at the time of filing. The court emphasized that claims covering broad chemical families require robust disclosure of the family’s scope — not just a handful of examples and an aspirational description of the rest.
Key Takeaways
- Broad genus claims covering vast chemical families require robust enablement: the specification must enable the skilled artisan to make and use the full scope of the claimed genus without undue experimentation, not just a few representative examples.
- Written description requires that the inventor show possession of the full scope of the genus — not merely a concept or a few examples — at the time of filing.
- A patent that claims billions of compounds but teaches synthesis of only a small number faces serious invalidity risk, even if the concept is sound and competitors later develop successful compounds within the genus.
- The decision protected Gilead’s sofosbuvir — worth tens of billions of dollars — from a patent covering broadly claimed but inadequately disclosed technology.
Why It Matters
Idenix v. Gilead is one of the largest patent invalidity decisions in history by the dollar value at stake: a $2.54 billion jury verdict was overturned because the underlying patent did not adequately disclose how to practice what it claimed. The case is a cautionary tale about claiming broadly without disclosing sufficiently in the pharmaceutical and chemistry space.
For drug developers and biotech companies, it reinforces that patent strategy must be grounded in what the inventors actually knew and disclosed at the time of filing. Attempts to write broad claims that sweep in later-developed compounds or approaches risk invalidity for lack of enablement or written description. The case also raised important questions about the competitive dynamic in HCV drug development, where multiple companies raced to develop treatments based on similar nucleoside chemistry.